These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25422486)

  • 41. Smoldering multiple myeloma: present position and potential promises.
    Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
    Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard.
    Fonseca R; Gonzalez-Velez M
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
    Brioli A; Melchor L; Cavo M; Morgan GJ
    Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
    Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
    Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overview of drug therapy for multiple myeloma.
    Saunders G
    J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic microenvironment and personalized treatment in multiple myeloma.
    Rossi M; Botta C; Correale P; Tassone P; Tagliaferri P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S83-93. PubMed ID: 23692463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular basis of clonal evolution in multiple myeloma.
    Furukawa Y; Kikuchi J
    Int J Hematol; 2020 Apr; 111(4):496-511. PubMed ID: 32026210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.
    Amodio N; Di Martino MT; Neri A; Tagliaferri P; Tassone P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S125-37. PubMed ID: 23692413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The multiple myeloma--current view and perspectives].
    Knop S
    Med Monatsschr Pharm; 2014 Mar; 37(3):84-92; quiz 93-4. PubMed ID: 24741848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
    Richardson PG; Laubach J; Mitsiades CS; Schlossman R; Hideshima T; Redman K; Chauhan D; Ghobrial IM; Munshi N; Anderson KC
    Br J Haematol; 2011 Sep; 154(6):755-62. PubMed ID: 21732930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel agents and the paradigm of continuous treatment in multiple myeloma.
    Palumbo A
    Leuk Res; 2012 Nov; 36 Suppl 1():S1-2. PubMed ID: 23176718
    [No Abstract]   [Full Text] [Related]  

  • 54. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
    Kuroda J; Kobayashi T; Taniwaki M
    Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial treatment of nontransplant patients with multiple myeloma.
    Cerrato C; Palumbo A
    Semin Oncol; 2013 Oct; 40(5):577-84. PubMed ID: 24135402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.
    Mohyuddin GR; Chakraborty R; Cliff ERS; Derman BA
    EClinicalMedicine; 2023 Nov; 65():102272. PubMed ID: 38046471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of asymptomatic myeloma patients.
    Mateos MV
    Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.